Comparison of Peri-lesional Triamcinolone Acetonide versus Incision and Curettage in the Treatment of Primary Chalazion
Doi: 10.36351/pjo.v38i1.1290
DOI:
https://doi.org/10.36351/pjo.v38i1.1290Abstract
Purpose: To compare the results of peri-lesional Triamcinolone Acetonide (TA) with incision and curettage in the treatment of primary chalazia.
Study Design: Quasi experimental study.
Place and Duration of Study: Eye department of District Head Quarter/Teaching Hospital, Gujranwala, from June 2018 to May 2019.
Methods: One hundred and twenty patients with primary chalazion, either gender and age between 10–30 years, were enrolled in this study. They were equally divided into two groups. In group A, incision and curettage was done. In group B, perilesional TA (40 mg/ml) was given. Followup was done at 5th day, 14th day, 1 month and 3 months. Lesion resolution or recurrence and complications were recorded. IOP monitoring was also carried out at each followup.
Results: Mean age was 18.0 ± 2.14 years with range of 10 – 30 years. There were 45.0% females and 55.0% males. No statistically significant difference was found in age, gender and complication rates between the two groups. Complete resolution was seen in 95.0% in group A and 88.3% cases in group B. The difference between the two groups was not statistically significant regarding small and medium sized chalazia. In case of large chalazia, 23 out of 24 patients in group A and 19 out of 23 patients in group B showed complete resolution and the difference in success rate of two groups was statistically significant (p = 0.014).
Conclusion: Incision and curettage and perilesional TA injection are equally effective in treating small and medium primary chalazia. While for large chalazia, Incision and curettage offered superior results.
Key words: Chalazion, incision and curettage, triamcinolone Acetonide,
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Hafiza Sadia Imtiaz, Aamna Jabran, Amna Anam, Wasim Ghous
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.